Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B435803fdffb1ba1d38b2f3b30c00fcef> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B435803fdffb1ba1d38b2f3b30c00fcef NCIT_P378 "NCI" @default.
- B435803fdffb1ba1d38b2f3b30c00fcef type Axiom @default.
- B435803fdffb1ba1d38b2f3b30c00fcef annotatedProperty IAO_0000115 @default.
- B435803fdffb1ba1d38b2f3b30c00fcef annotatedSource NCIT_C70741 @default.
- B435803fdffb1ba1d38b2f3b30c00fcef annotatedTarget "A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells." @default.